Which alternative funding options to VCs for biotech & MedTech start-ups?

Edition

Which alternative funding options to VCs for biotech & MedTech start-ups?

There is more money than ever fuelling the biotech and MedTech industries, and different kind of investors are entering the stage with more influence than previously thought possible. Which options are there? What do you need to identify these funding sources? What are the expectations and specificities of working with angel investors, disease foundations, private equity firms, cross-over funds and family offices? What are the best funding strategies for biotech & MedTech start-ups?

Andreas Schmidt

CEO, Board Director
Germany
Proteona

Jamie Kemler

VP, Intellectual Property Business Strategy
USA
Stryker

Stefano Marzario

Senior Investment Officer
Luxembourg
European Investment Bank

Rémi Soula

Founding Partner, Entrepreneur in Residence
France
Argobio

Tobias Silberzahn

Partner
Germany
McKinsey & Company
  • No products in the cart.